by jtcir-auto | Apr 7, 2020 | Press Releases
– Modifications recommended for some key elements of planned safety and efficacy Study P02 — Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol complying with requirements from EMA as well as FDA -CHARLESTON,...
by jtcir-auto | Apr 6, 2020 | Press Releases
– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic — Pediatric PK/PD profile of macimorelin proved to be in the expected range and generally...
by jtcir-auto | Apr 6, 2020 | Press Releases
– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic — Pediatric PK/PD profile of macimorelin proved to be in the expected range and generally...
by jtcir-auto | Mar 30, 2020 | Press Releases
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ — Robust ongoing business development discussions to secure a commercialization partner for macimorelin in Europe...
by jtcir-auto | Mar 30, 2020 | Press Releases
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ — Robust ongoing business development discussions to secure a commercialization partner for macimorelin in Europe...
by jtcir-auto | Mar 12, 2020 | Press Releases
CHARLESTON, S.C., March 12, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...